266 related articles for article (PubMed ID: 25237156)
1. Colistin- and polymyxin-induced nephrotoxicity: focus on literature utilizing the RIFLE classification scheme of acute kidney injury.
Pike M; Saltiel E
J Pharm Pract; 2014 Dec; 27(6):554-61. PubMed ID: 25237156
[TBL] [Abstract][Full Text] [Related]
2. Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B?
Zavascki AP; Nation RL
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993859
[TBL] [Abstract][Full Text] [Related]
3. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center.
Akajagbor DS; Wilson SL; Shere-Wolfe KD; Dakum P; Charurat ME; Gilliam BL
Clin Infect Dis; 2013 Nov; 57(9):1300-3. PubMed ID: 23840000
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium.
Tuon FF; Rigatto MH; Lopes CK; Kamei LK; Rocha JL; Zavascki AP
Int J Antimicrob Agents; 2014 Apr; 43(4):349-52. PubMed ID: 24439066
[TBL] [Abstract][Full Text] [Related]
5. Nephrotoxicity in Patients with or without Cystic Fibrosis Treated with Polymyxin B Compared to Colistin.
Crass RL; Rutter WC; Burgess DR; Martin CA; Burgess DS
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167560
[TBL] [Abstract][Full Text] [Related]
6. Multicenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B.
Rigatto MH; Oliveira MS; Perdigão-Neto LV; Levin AS; Carrilho CM; Tanita MT; Tuon FF; Cardoso DE; Lopes NT; Falci DR; Zavascki AP
Antimicrob Agents Chemother; 2016 Apr; 60(4):2443-9. PubMed ID: 26856846
[TBL] [Abstract][Full Text] [Related]
7. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy.
Phe K; Lee Y; McDaneld PM; Prasad N; Yin T; Figueroa DA; Musick WL; Cottreau JM; Hu M; Tam VH
Antimicrob Agents Chemother; 2014 May; 58(5):2740-6. PubMed ID: 24566187
[TBL] [Abstract][Full Text] [Related]
8. Polymyxin-induced nephrotoxicity and its predictors: a systematic review and meta-analysis of studies conducted using RIFLE criteria of acute kidney injury.
Sisay M; Hagos B; Edessa D; Tadiwos Y; Mekuria AN
Pharmacol Res; 2021 Jan; 163():105328. PubMed ID: 33276108
[TBL] [Abstract][Full Text] [Related]
9. Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy.
Kubin CJ; Ellman TM; Phadke V; Haynes LJ; Calfee DP; Yin MT
J Infect; 2012 Jul; 65(1):80-7. PubMed ID: 22326553
[TBL] [Abstract][Full Text] [Related]
10. Nephrotoxicity prevalence in patients treated with polymyxins: a systematic review with meta-analysis of observational studies.
Oliota AF; Penteado ST; Tonin FS; Fernandez-Llimos F; Sanches AC
Diagn Microbiol Infect Dis; 2019 May; 94(1):41-49. PubMed ID: 30635223
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study.
Rigatto MH; Behle TF; Falci DR; Freitas T; Lopes NT; Nunes M; Costa LW; Zavascki AP
J Antimicrob Chemother; 2015 May; 70(5):1552-7. PubMed ID: 25604744
[TBL] [Abstract][Full Text] [Related]
12. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center.
Hartzell JD; Neff R; Ake J; Howard R; Olson S; Paolino K; Vishnepolsky M; Weintrob A; Wortmann G
Clin Infect Dis; 2009 Jun; 48(12):1724-8. PubMed ID: 19438394
[TBL] [Abstract][Full Text] [Related]
13. Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis.
Vardakas KZ; Falagas ME
Int J Antimicrob Agents; 2017 Feb; 49(2):233-238. PubMed ID: 27686609
[TBL] [Abstract][Full Text] [Related]
14. Nephrotoxicity associated with intravenous colistin in critically ill patients.
Doshi NM; Mount KL; Murphy CV
Pharmacotherapy; 2011 Dec; 31(12):1257-64. PubMed ID: 22122186
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for acute kidney injury in patients treated with polymyxin B at a Tertiary Care Medical Center.
Bahlis LF; Diogo LP; Lemons D; Klaus D
J Bras Nefrol; 2015; 37(4):446-50. PubMed ID: 26648493
[TBL] [Abstract][Full Text] [Related]
16. Comparison of nephrotoxicity of Colistin with Polymyxin B administered in currently recommended doses: a prospective study.
Aggarwal R; Dewan A
Ann Clin Microbiol Antimicrob; 2018 Mar; 17(1):15. PubMed ID: 29571295
[TBL] [Abstract][Full Text] [Related]
17. Battle of polymyxin induced nephrotoxicity: Polymyxin B versus colistin.
Ballı FN; Ekinci PB; Kurtaran M; Kara E; Dizman GT; Sönmezer MÇ; Hayran M; Demirkan K; Metan G
Int J Antimicrob Agents; 2024 Feb; 63(2):107035. PubMed ID: 37979889
[TBL] [Abstract][Full Text] [Related]
18. Colistin versus polymyxin B: A pragmatic assessment of renal and neurological adverse effects and effectiveness in multidrug-resistant Gram-negative bacterial infections.
Simon V; Viswam A; Alexander PS; James E; Sudhindran S
Indian J Pharmacol; 2023; 55(4):229-236. PubMed ID: 37737075
[TBL] [Abstract][Full Text] [Related]
19. Nephrotoxicity Associated with Intravenous Polymyxin B Once- versus Twice-Daily Dosing Regimen.
Okoduwa A; Ahmed N; Guo Y; Scipione MR; Papadopoulos J; Eiras DP; Dubrovskaya Y
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29844039
[TBL] [Abstract][Full Text] [Related]
20. Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity.
Oliveira MS; Prado GV; Costa SF; Grinbaum RS; Levin AS
Diagn Microbiol Infect Dis; 2009 Dec; 65(4):431-4. PubMed ID: 19733029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]